Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial

BACKGROUND: Major depressive disorder (MDD) is a prevalent and disabling disorder that can lead to heavy individual, familial, and societal burdens. Although pharmaceutical interventions still play an essential role in therapeutic measures, limitations, including effects that are delayed for weeks,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jingjing, Wang, Weiwei, Yang, Jian, Zhu, Xuequan, Feng, Lei, Xiao, Le, Wang, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327471/
https://www.ncbi.nlm.nih.gov/pubmed/30626409
http://dx.doi.org/10.1186/s13063-018-3132-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327471/
https://www.ncbi.nlm.nih.gov/pubmed/30626409
http://dx.doi.org/10.1186/s13063-018-3132-3

Ejemplares similares